Sequential Administration of Dihuang Baoyuan Granules and Fuling Yunhua Granules for Teating Type 2 Diabetes Mellitus in Mice
10.13422/j.cnki.syfjx.20250436
- VernacularTitle:地黄宝源颗粒和茯苓运化颗粒标本序贯给药治疗小鼠自发性2型糖尿病
- Author:
Huiyi XIE
1
;
Junran CHEN
1
;
Boning HUANG
1
;
Xinrong YANG
1
;
Fangle LIU
1
;
Yuying ZHENG
1
;
Haiyu ZHAO
2
;
Tianbao HU
3
;
Baoqin LIN
1
Author Information
1. The First Affiliated Hospital of Guangzhou University of Chinese Medicine， Guangdong Clinical Research Academy of Chinese Medicine， Guangdong Engineering Research Center of Commercialization of Medical Institution Preparations and Traditional Chinese Medicines， Guangdong Engineering Technology Research Center of Commercialization of Linnan Special Medical Institution Preparations， Guangzhou 510405， China
2. State Key Laboratory for Quality Ensurance and Sustainable Use of Dao-di Herbs， Institute of Chinese Materia Medica， China Academy of Chinese Medical Sciences， Beijing 100700， China
3. Hu Tianbao Community-Level Old Chinese Medicine Studio， Beijing 100700， China
- Publication Type:Journal Article
- Keywords:
Dihuang Baoyuan granules;
Fuling Yunhua granules;
type 2 diabetes mellitus;
diabetic retinopathy;
sequential administration
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2025;31(11):155-163
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo investigate the therapeutic effect of sequential administration of Dihuang Baoyuan granules （DHBY， the prescription for consolidating body resistance） and Fuling Yunhua granules （FLYH， the prescription for treating symptoms） on spontaneous type 2 diabetes mellitus （T2DM） in mice. MethodsAccording to the fasting blood glucose （FBG） level， 12-week-old db/db mice were randomized into six groups： model， DHBY （18.02 g·kg-1）， FLYH （14.80 g·kg-1）， sequential administration 1 （SEQ-1， DHBY 18.02 g·kg-1+FLYH 14.80 g·kg-1）， sequential administration 2 （SEQ-2， FLYH 14.80 g·kg-1+DHBY 18.02 g·kg-1）， and dapagliflozin （Dapa， 1.3 mg·kg-1）. The m/m mice in the same litter were selected as the normal group. The mice were administrated with corresponding drugs by gavage for 8 consecutive weeks. During the 8 weeks of drug administration and 2 weeks after withdrawal， the retinal thickness， FBG， hemoglobin A1c （HbA1c）， and insulin were determined， and histopathological changes of the pancreas， liver， kidney， and retina were observed by hematoxylin-eosin （HE） staining. ResultsCompared with the model group， SEQ-1 for 4 weeks lowered the FBG level （P<0.05）， raised the insulin level， decreased the triglyceride （TG） level （P<0.05）， increased the number of optic ganglion cells and diminished vacuolar degeneration of pancreatic islet and liver. SEQ-2 lowered FBG and HbA1c levels （P<0.05）， rose the insulin level， increased the retinal thickness and the number of optic ganglion cells （P<0.05）， and alleviated vacuolar degeneration of pancreatic islet and liver. Two weeks after drug withdrawal， Dapa tended to increase FBG and HbA1c compared with those at the time of drug withdrawal. However， the levels of FBG and HbA1c in the SEQ-2 group remained decreasing （P<0.05）. ConclusionSEQ-1 and SEQ-2 can lower the blood glucose level and ameliorate diabetic retinopathy， and SEQ-2 outperformed DHBY and FLYH in lowering the blood glucose level. Moreover， SEQ-2 can maintain the blood glucose-lowering effect after drug withdrawal.
